Brivaracetam is a new antiepileptic drug with limited data in children. The objective of this study was to assess the efficacy/tolerability of brivaracetam. This is a retrospective chart review of children/adolescents with refractory epilepsy treated with brivaracetam from 2016 to 2018. The primary outcome was seizure reduction (decrease in seizure frequency >50%). Twenty-three patients were identified. Mean age at initiation was 12.5 years. Fourteen were females. Epilepsy was focal in 11, generalized in 6, and mixed in 3. Average dose was 3.9 mg/kg/d. The mean duration of treatment was 8.2 months. Eight had greater than 50% decrease in seizure frequency, of which 7 had focal epilepsy, and 1 had Lennox-Gastaut/mixed epilepsy. Two had drowsiness and 3 behavioral complaints. One experienced tingling and dizziness. Our retrospective review suggests that brivaracetam is an effective therapy for refractory focal epilepsy in children older than 4 years of age.
AabergKMGunnesNBakkenIJ, et al.Incidence and prevalence of childhood epilepsy: a nationwide cohort study. Pediatrics. 2017;139(5).
2.
YatesSLFakhouryTLiangWEckhardtKBorghsSD’SouzaJ. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(pt A):165–168.
Seker YilmazBOkuyazCKomurM. Predictors of intractable childhood epilepsy. Pediatr Neurol. 2013;48(1):52–55.
5.
FDA approves Briviact to treat partial onset seizures [press release]. www.fda.gov: U.S. Food and Drug Administration; 2016.
6.
Amengual-GualMSánchez FernándezIWainwrightMS. Novel drugs and early polypharmacotherapy in status epilepticus. Seizure. 2019;68:79–88.
7.
RussoECitraroRMulaM. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. Expert Opin Drug Discov. 2017;12(11):1169–1178.
8.
SchoemakerRWadeJRStockisA. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017;73(6):727–733.
9.
HalmaEde LouwAJKlinkenbergSAldenkampAPIJffDMMajoieM. Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. Seizure. 2014;23(9):685–691.
10.
MbizvoGKDixonPHuttonJLMarsonAG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012(9):CD001901.
11.
ChenDBianHZhangL. A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy. Neuropsychiatr Dis Treat. 2019;15:905–917.
12.
CaoYHeXZhaoL, et al.Efficacy and safety of levetiracetam as adjunctive treatment in children with focal onset seizures: a systematic review and meta-analysis. Epilepsy Res. 2019;153:40–48.
13.
FrenchJACostantiniCBrodskyAvon RosenstielPGroupNS. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–525.
14.
Van PaesschenWHirschEJohnsonMFalterUvon RosenstielP. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97.
15.
BitonVBerkovicSFAbou-KhalilBSperlingMRJohnsonMELuS. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66.
16.
KleinPSchiemannJSperlingMR, et al.A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898.
17.
KwanPTrinkaEVan PaesschenWRektorIJohnsonMELuS. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38–46.
18.
ArzimanoglouAD’CruzONordliDShinnarSHolmesGL, Pediatric Epilepsy Academic Consortium for Extrapolation (PEACE). A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Paediatr Drugs. 2018;20(3):249–264.
19.
SchoemakerRWadeJRD’SouzaJStockisA. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures. Epilepsy Res. 2017;137:95–100.
20.
WillemsLMBertscheABösebeckF, et al.Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018;9:569.
21.
StrzelczykAKayLBauerS, et al.Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59(8):1549–1556.
22.
VillanuevaVLópez-GonzálezFJMauriJA, et al.BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139(4):360–368.
23.
HirschMHintzMSpechtASchulze-BonhageA. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98–103.
24.
Schubert-BastSWillemsLMKurlemannG, et al.Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89–93.
